Plain-English translation of NCT06574620 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether genetic information from your pancreatic cancer tumor can help doctors choose the best chemotherapy for you. Researchers will collect samples of your tumor, blood, and fluid during your standard surgery and treatment, then analyze the genetic makeup of your cancer to understand how it might respond to chemotherapy like FOLFIRINOX or gemcitabine-based regimens. The goal is to make treatment decisions faster and more personalized to your specific cancer.
Pancreatic cancer is difficult to treat, and not all patients respond the same way to the same chemotherapy. This study exists to see whether understanding your tumor's genetic profile early in your treatment can help doctors predict which medications will work best for you and potentially improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive standard chemotherapy as planned with your oncologist. During your standard surgery, doctors will collect tissue samples, and they may take additional small biopsy samples if you agree. Blood samples will be collected at multiple visits throughout your treatment. You will visit the clinic every 4 weeks for checkups and tests, and complete short questionnaires every 12 weeks. The genetic testing of your samples happens in the background to help inform your care.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Canada